Rapport Therapeutics (RAPP) Reiterated at Buy by Stifel
Tweet Send to a Friend
(Updated - September 16, 2026 9:35 AM EDT)
Stifel analyst Paul Matteis reiterated a Buy rating and $56.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis reiterated a Buy rating and $56.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
